News Results for Motif Bio Ord 1p (MTFB)

Cash shell Motif Bio said it was in negotiations with several reverse takeover candidates in the healthcare sector. The company also announced that it had hired Peel Hunt as an adviser to help it...

Cash shell Motif Bio said it had raised £0.65m via a share placing to an institutional investor. New shares in the company were issued at 0.4p each. Proceeds would be used to strengthen the...

Motif Bio, which was recently reclassified as a cash shell, said chief executive Graham Lumsden had stood down and become a non-executive director. Chief financial officer Jonathan Gold had...

Motif Bio said it had given notice to Bank of New York Mellon to terminate its American depositary shares program and warrant agent agreement. The move came after the company on Monday announced...

Antibiotics developer Motif Bio said five of its non-executive directors had stood own as part of move to minimise costs and preserve capital. Craig Albanese, Charlotta Ginman, Zaki Hosny, Mary...

Motif Bio said a subsidiary had reached agreement with its former clinical research organisation to settle all obligations without further payment. The pact would result in the reversal of a...

Antibiotics developer Motif Bio said it had raised $0.6m from a share issue to provide additional working capital for a planned restructuring. New shares in the company were issued at 0.42p each....

Antibiotics developer Motif Bio said lender Hercules Capital had agreed to push back the company's next amortisation date to 1 October, from 1 September. The change would mean that the September...

Antibiotics developer Motif Bio said it would commence a study to evaluate the effectiveness of a treatment candidate against Listeria. Motif Bio said it would utilise NIAID's suite of preclinical...

Clinical-stage biopharmaceutical Motif Bio said its market value had slipped below a minimum threshold required for it to be listed on the Nasdaq. The company said it had received a deficiency...

Antibiotics developer Motif Bio said it had submitted a meeting request and package to the US Food & Drug Administration. The request was related to the company's lead product candidate,...

Motif Bio said new data regarding its antibiotic development work had been presented at a key conference in San Francisco. The iclaprim data were presented at the American Society For...

Motif Bio said it had signed an agreement with Otto-von-Guericke University Magdeburg to conduct a study evaluating iclaprim in an in-vitro model of ocular toxoplasmosis. The research would focus...

Motif Bio said it had signed an agreement with Lamellar Biomedical under which the companies would investigate a combination of their offerings. The arrangement would see Motif Bio conduct an in...

Antibiotics developer Motif Bio booked an narrower annual loss as it cut R&D spending. Pre-tax losses for the year through December amounted to $14.0m, narrowing from losses of $44.8m...

Antibiotics developer Motif Bio said it had raised £2.7m from a share placing to provide additional working capital. New shares in the company were issued at 6p each. The company recently...

Antibiotics developer Motif Bio said the US Food & Drug Administration had granted its request for a meeting to discuss iclaprim for the treatment of acute bacterial skin and skin structure...

Antibiotics developer Motif Bio said Richard C. E. Morgan had resigned with immediate effect to focus on other business commitments. Current director Bruce Williams has been appointed interim...

Antibiotic developer Motif Bio said it would need to raise capital after it made an early debt repayment to Hercules Capital. The company said it would make an immediate early repayment of $7m and...

Bio-pharmaceutical company Motif Bio said it would present data on its wound treatment at an industry conference in San Francisco. The data for its iclaprim treatment would be presented at IDWeek...

Antibiotics developer Motif Bio noted that substantial shareholder Amphion Innovations had agreed to repayment of a loan by one year until 30 September 2019. Amphion's loan facility was secured by...

Peel Hunt today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and cut its price target to 95p (from 102p). Story provided by StockMarketWire.com Broker Forecasts data...

Antibiotics developer Motif Bio booked a narrowing of first half losses after it cut back on R&D spending. Net losses for the six months through June narrowed to $7.8m, from $29.7m on-year....

Antibiotic developer Motif Bio said it was presenting data on the skin treatment iclaprim at an industry conference in Lisbon. The safety study data was being presented at the European Society of...

Antibiotics developer Motif Bio noted that Amphion Innovations had sold some of its holding in the company to an institutional investor. Amphion now held 8.51% of the issued share capital of Motif...

Motif Bio said data about its iclaprim antibiotic treatment would be presented at an upcoming industry conference in Lisbon. The European Society of Clinical Microbiology and Infectious Diseases...

Motif Bio said the US Food & Drug Administration had accepted for filing its new drug application for an antibiotic that treats acute bacterial skin and skin structure infections. The...

Northland Capital today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and set its price target at 116p. Story provided by StockMarketWire.com Broker Forecasts data...

Antibiotics developer Motif Bio said that Robert Bertoldi would resign from its board, effective 16 July. 'On behalf of the board, we are grateful to Bob for his dedication and service to the...

Motif Bio announced the completion of its rolling submission of a new drug application (NDA) to the US Food & Drug Administration (FDA) for iclaprim. Iclaprim is a targeted, Gram-positive...

Motif Bio said it had presented findings from a trail of a treatment for bacterial skin infections at a conference in Atlanta. Data from two Phase 3 trials of the investigational drug candidate...

Northland Capital today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and set its price target at 115p. Story provided by StockMarketWire.com Broker Forecasts data...

Peel Hunt today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and cut its price target to 102p (from 106p). Story provided by StockMarketWire.com Broker Forecasts data...

Antibiotics developer Motif Bio said annual losses deepened, partly due to a rise in staff remuneration costs as it grew its headcount. Pre-tax losses amounted to $44.8m, compared to red ink of...

Peel Hunt today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and set its price target at 106p. Story provided by StockMarketWire.com Broker Forecasts data provided by...

Antibiotic developer Motif Bio said it had initiated a rolling submission for a new drug application to the US Food & Drug Administration for a treatment for skin infections. The submission,...

Peel Hunt today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and cut its price target to 106p (from 107p). Story provided by StockMarketWire.com Broker Forecasts data...

Motif Bio said it had delayed a new drug application to the US Food and Drug Administration for a skin-infection treatment in order improve the quality of its submission. 'In consultation with its...

Motif Bio said chief financial officer Robert Dickey had resigned. A search process for a new CFO had commenced, the company said. Jonathan E. Gold, currently a non-executive director, had...

Motif Bio has filed a shelf registration statement with the US Securities and Exchange Commission, which it said would provide it with more timely and efficient access to the US capital markets....

Motif Bio said chief executive Graham Lumsden would participate in a panel discussion today at the Cantor Antibiotics Summit in New York. The topic of discussion is "Catalysts to Look for in...

Motif Bio has secured up to $20m in debt financing with Hercules Capital to fund preparation activities ahead of the US launch of iclaprim in 2019. The first tranche of $15m will be drawn down...

Motif Bio has presented new pre-clinical data regarding its investigational drug candidate iclaprim to the IDWeek 2017 conference in San Diego. "The data presented today underscore the potential...

Peel Hunt today initiates coverage of Motif Bio Plc Ord 1p (LON:MTFB) with a buy investment rating and price target of 106p. Story provided by StockMarketWire.com

UK Prime Minister Theresa May's proposed energy cap dragged on UK-listed energy giants British Gas owner Centrica (CNA) and SSE (SSE). Shares in Centrica slumped 6.1% to 179.3p and SSE declined...

The FTSE 100 was weighed down by weakness in utility stocks and Royal Dutch Shell (RDSB), causing the index to dip to 7,464. Rumours that UK Prime Minister Theresa May would bring in an energy cap...

Motif Bio reported a net loss for the six months ended 30 June 2017 and 2016 was $29.7m and $14.2m, respectively. BUSINESS UPDATE: - On April 18 2017, we announced positive top-line results from...

Motif Bio has confirmed that the Company will be presenting at the Rodman & Renshaw 19th Annual Global Investment Conference, to be held between the 10th and 12th of September. In addition,...

finnCap today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and cut its price target to 100p (from 125p). Story provided by StockMarketWire.com

The FTSE 100 is jogging higher in early deals thanks to gains across a palette of sectors, although the resources sector was under pressure. The early rise came after the US last night flagged it...

Motif Bio intends to raise about £19.4m via a conditional placing with new and existing investors to fund the further development of iclaprim, its novel antibiotic candidate. The placing was being...

Story provided by StockMarketWire.com

As investors returned to the UK markets following the long Easter weekend, there was little corporate news to stir the FTSE 100. Commodity prices slumped across the board with iron and copper the...

Motif Bio announced positive topline results from REVIVE-1, a global Phase 3 clinical trial of its investigational drug candidate iclaprim in patients with acute bacterial skin and skin structure...

finnCap today initiates coverage of Motif Bio Plc Ord 1p (LON:MTFB) with a buy investment rating and price target of 125p. Story provided by StockMarketWire.com

Beaufort Securities today reaffirms its speculative buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and set its price target at 110p. Story provided by StockMarketWire.com

Motif Bio says the last patient has finished the treatment phase in REVIVE-1, the Phase 3 clinical trial investigating the safety and efficacy of iclaprim in patients with acute bacterial skin and...

Story provided by StockMarketWire.com

Motif Bio said that Robert Dickey IV has been appointed as Chief Financial Officer. It said Pete Meyers is leaving the company and has agreed to transition the CFO responsibilities to Dickey over...

Story provided by StockMarketWire.com

Northland Capital today reaffirms its buy investment rating on Motif Bio Plc Ord 1p (LON:MTFB) and cut its price target to 90p (from 140p). Story provided by StockMarketWire.com

Story provided by StockMarketWire.com

Motif Bio has provided an update on REVIVE-1, one of its two Phase 3 clinical trials currently enrolling patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Patient...

Story provided by StockMarketWire.com

Beaufort Securities today downgrades its investment rating on Motif Bio Plc Ord 1p (LON:MTFB) to hold (from speculative buy). Story provided by StockMarketWire.com

Motif Bio widens H1 pretax loss of $14.2m, from a loss of $1.9m. It is pleased that lead product iclaprim is in its final stage of development. This followed the the dosing of the first patient...

Story provided by StockMarketWire.com

Motif Bio said that due to market conditions it has deferred pricing of its proposed public offering of American Depositary Shares and listing of these on the NASDAQ Global Market. "However, the...

Story provided by StockMarketWire.com

Amphion Innovations' partner company Motif Bio has filed a registration with the US Securities and Exchange Commission for a proposed public offering American Depositary Shares. Motif Bio has also...

Motif Bio has filed a registration statement on Form F-1 with the US Securities and Exchange Commission (SEC) relating to a proposed public offering of American Depositary Shares (ADSs). Motif...

Story provided by StockMarketWire.com

Motif Bio has confirmed that all resolutions proposed at its annual general meeting today were passed. At 3:40pm: (LON:MTFB) Motif Bio Plc Ord 1p share price was -1p at 51p Story provided by...

Motif Bio has materially widened its FY pretax loss to USD8.5m, from a year-earlier loss of USD1.2m. General and administrative expenses rose to USD3.6m, from USD1.1m, while R&D expenses hit...

Story provided by StockMarketWire.com

Story provided by StockMarketWire.com

Motif Bio confirms the dosing of the first patient in two Phase 3 clinical trials of its lead antibiotic candidate iclaprim, for the treatment of acute bacterial skin and skin structure infections...

Story provided by StockMarketWire.com

Story provided by StockMarketWire.com

Motif Bio said clinical trial supplies in the form of sterile ampoules of iclaprim have been manufactured. Following Quality Assurance release, these supplies will be shipped to clinical trial...

Story provided by StockMarketWire.com

Motif Bio, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has been selected to present at the Biotech Showcase 2016, San Francisco, on 11 January at...

Motif Bio has received written concurrence from the US Food & Drug Administration (FDA) for an optimized fixed dose of iclaprim of 80mg for all patients except those with moderate hepatic...

Story provided by StockMarketWire.com

Motif Bio (MTFB) (MTFB.L) [LON.MTFB], a clinical stage biopharmaceutical company specialising in developing novel antibiotics, will be giving a briefing to investors in London early next month. It...

Motif Bio confirms the signing of a Phase III clinical trials agreement with Covance, a Contract Research Organisation (CRO) and subsidiary of Laboratory Corp. The trials are for iclaprim, a...

Story provided by StockMarketWire.com

John Stakes, Non Executive Director, bought 100,000 shares in the company on the 2nd October 2015 at a price of 60.00p. The Director now holds 171,850 shares. Story provided by...

Motif Bio has announced that it has issued 140,321 new Ordinary Shares in settlement of an exercise of warrants. The exercise price of the warrants was 20 pence. The new Ordinary Shares represent...

Motif Bio said the US Food and Drug Administration (FDA) has granted Fast Track designation for iclaprim intravenous (IV) to treat Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and...

Story provided by StockMarketWire.com

Motif Bio has appointed Westwicke Partners as investor relations adviser in the US. Motif chief executive Graham Lumsden said: "We look forward to building a relationship with the Westwicke team...

Motif Bio (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has announced its maiden interim financial results as an AIM-listed company. The...

Story provided by StockMarketWire.com

Motif Bio has issued 25,147 ordinary shares following the exercise of options by a former employee. The options were exercised at prices of $0.20877 and $0.69589 per ordinary share for total...

Motif Bio said the US Food & Drug Administration (FDA) has designated iclaprim as a Qualified Infectious Diseases Product (QIDP) for hospital acquired bacterial pneumonia (HABP) Iclaprim is a...

Story provided by StockMarketWire.com

Motif Bio has announced that at the General Meeting held earlier today all resolutions were duly passed. At 1:40pm: (LON:MTFB) Motif Bio Plc Ord 1p share price was 0p at 64p Story provided...

Amphion Innovations partner company Motif Bio has raised £22m, gross, through a conditional placing of 44,000,000 new ordinary shares at 50p apiece with institutional investors. The placing is...